August 2008- Volume 4, Issue 8

In this Issue

Informatics

Finding the needle in the haystack

Finding the needle in the haystack

Thermo Fisher and Genedata form mass spec partnership

No gene left behind

No gene left behind

Sophic and Biomax receive funds to complete NCI's Cancer Gene Index Project

Out with the old

Out with the old

Channing Lab phases out Legacy LIMS with LabVantage’s SAPPHIRE

British bioscience booster shot

British bioscience booster shot

GSK, Univ. of Manchester ally to bridge research gaps in U.K.

High-throughput triple team

High-throughput triple team

Applied Bio and Integromics collaborate with Novartis on high-throughput analysis platform

Automation & Instrumentation

Short-hairpin, long view

Short-hairpin, long view

Thermo Fisher buys Open Biosystems and adds company's shRNA lentiviral library to its growing RNAi portfolio

Affinity for acquisitions

Affinity for acquisitions

Thermo Fisher buys Affinity BioReagents

Iongate’s SURFE²R is up

Iongate’s SURFE²R is up

IonGate taps Artel to spearhead adoption and application of SURFE²R technology in North America

Paying the price for PCR

Paying the price for PCR

Qiagen buys Australia’s Corbett Life Sciences in deal that could eventually top $130 million

Research & Development

Cinryze and synergy

Cinryze and synergy

ViroPharma acquires Lev Pharmaceuticals and inflammatory disease program

No-nonsense drug discovery

No-nonsense drug discovery

Genzyme and PTC Therapeutics to develop small molecule for genetic diseases

Go fish

Go fish

Znomics, OHSU use zebrafish screening to identify inflammatory disease therapeutics

FAST pharma friends

FAST pharma friends

Lilly acquires oncology biotech SGX Therapeutics for $64 million

Wider gap in generics

Wider gap in generics

Teva snaps up Barr for $7.4 B

Feature

Rise of next-gen genomics

Rise of next-gen genomics

The Human Genome Project was just the start; NIH is pushing hard on the genomics envelope

Genomics & Proteomics

Wake up and die

Wake up and die

Duke researchers may be on to a way to activate herpes long enough to kill it

U.W.’s new fly in the ointment

U.W.’s new fly in the ointment

Research uncovers new ‘pressure points’ against flu

U of Minn. spearheads guidance on incidental findings

U of Minn. spearheads guidance on incidental findings

When one thinks of byproducts of pharmaceutical research, biomedical waste might be the first thing that comes to mind for most, but an increasing area of concern is the leftover incidental health findings, says Susan Wolf, J.D., who chairs the University of Minnesota’s Consortium on Law and Values in Health, Environment and the Life Sciences.

A nose for opportunity

A nose for opportunity

Nastech becomes mdRNA and moves RNAi tech ahead of nasal delivery

Protein power

Protein power

Althea Technologies and Protein'eXpert accord connects early- and late-stage needs for client projects

Patent News

Synergy won’t get you a patent term extension

Synergy won’t get you a patent term extension

One way drug companies are compensated for the regulatory burden of seeking FDA approval is the extension of patent terms. One of the eligibility requirements for a patent term extension is that the permission for the commercial marketing or use of the product be the first permitted commercial marketing or use of the product.

Editor's Focus

How soon does 2015 seem to you?

How soon does 2015 seem to you?

Seven years ago, Genentech shares were trading for roughly $22 per share and Roche had been the majority owner of the company for a bit more than 10 years. In 2001, with agreements in place that would provide Roche with first choice to pick Genentech’s ripest fruit, I’m sure 2015 seemed forever in the future. But not anymore.

Global News

Genentech no more?

Genentech no more?

Roche offers $43.7 billion for remainder of Genetech shares

Stop the bleeding

Stop the bleeding

Bayer HealthCare acquires Maxygen’s hemophilia assets for up to $120 million

Summit lands $143M license deal

Summit lands $143M license deal

Summit Corp. plc and California-based BioMarin Pharmaceutical Inc. announced late last month they the companies inked an exclusive worldwide licensing agreement for Summit’s novel preclinical candidate SMT C1100 and all follow-on molecules, which are being developed to treat the fatal genetic disorder Duchenne muscular dystrophy (DMD).

Tropical diseases tested

Tropical diseases tested

Upstream Biosciences, McGill University to collaborate on tropical disease treatment testing

Immunomedics, Nycomed in veltuzumab deal

Immunomedics, Nycomed in veltuzumab deal

Immunomedics Inc. and Nycomed GmbH recently announced a license and collaboration agreement providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, Immunomedics’ humanized anti-CD20 antibody in a subcutaneous formulation for the treatment of all non-cancer indications.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 17 • Issue 1 • January 2021

December 2020/January 2021

December 2020/January 2021 issue